IMEP (chemotherapy)
IMEP is a chemotherapy regimen that is effective for nasal NK-/T-cell lymphoma.[1] This chemotherapy regimen was also tested in Hodgkin lymphoma as a part of a multidrug alternating scheme COPP/ABV/IMEP. But in that setting it showed no advantage in efficacy and toxicity compared to the use of ABVD or the alternating COPP/ABVD scheme.[2]
Drug regimen
| Drug | Dose | Mode | Days |
|---|---|---|---|
| Ifosfamide | 1500 mg/m2 with mesna | IV infusion | Days 1-3 |
| Methotrexate | 30 mg/m2 | IV bolus | Days 3 and 10 |
| Etoposide | 100 mg/m2 | IV infusion | Days 1-3 |
| Prednisone | 120 mg | PO qd | Days 1-5 |
References
- ↑ "IMEP protocol in nasal NK/T-cell lymphoma". Retrieved 2014-09-11.
{{cite web}}: CS1 maint: deprecated archival service (link) - ↑ Treatment of advanced Hodgkin’s disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin’s Lymphoma Study Group HD6 trial[link removed]
Category: